Clinical implications of EGFR‐associated MAPK/ERK pathway in multiple primary lung cancer
Clinical implications of EGFR‐associated MAPK/ERK pathway in multiple primary lung cancer
About this item
Full title
Author / Creator
Liang, Naixin , Bing, Zhongxing , Wang, Yadong , Liu, Xinyu , Guo, Chao , Cao, Lei , Xu, Yuan , Song, Yang , Gao, Chao , Tian, Zhenhuan , Wu, Pancheng , Xue, Jianchao , Li, Bowen , Jia, Ziqi , Yang, Xiaoying , Wu, Yijun , Yu, Ruoying , Liu, Rui , Chen, Xiaoxi , Ou, Qiuxiang , Bao, Hua , Wu, Xue , Cao, Zhili , Li, Ji and Li, Shanqing
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
In multiple primary lung cancers (MPLCs), surgery achieved a 5-year overall survival rate that varies from 27.4% to 95.8%.1 Targeted therapy has been applied to MPLC patients with different responses due to driver mutation heterogeneity.2 Meanwhile, two clinical trials are testing immune checkpoint inhibitors for MPLCs (NCT04026841; NCT04047186). P...
Alternative Titles
Full title
Clinical implications of EGFR‐associated MAPK/ERK pathway in multiple primary lung cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1f2475a814ec4241a1426bd29fa299de
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1f2475a814ec4241a1426bd29fa299de
Other Identifiers
ISSN
2001-1326
E-ISSN
2001-1326
DOI
10.1002/ctm2.847
